Kinevant Sciences is on a mission to transform the lives of people living with rare inflammatory diseases through high-impact medicine. Kine is a word from Ancient Greece meaning “to move” or “set in motion,” which defines our purpose of moving safe and accessible therapeutics forward, so patients feel empowered to take back full control of their lives. Our approach combines patient-forward thinking, scientific rigor and clinical excellence to overcome some of the most deep-rooted barriers to treatment within underserved populations by delivering disease-modifying therapeutics that are safe, well tolerated and easily accessible. Our lead product candidate, namilumab, is an investigational monoclonal antibody being developed for treatment of sarcoidosis. Namilumab has the potential to address the underlying disease pathology by targeting GM-CSF, a key pro-inflammatory cytokine and growth factor implicated in the pathogenesis of sarcoidosis and other inflammatory disorders. Kinevant has initiated two actively enrolling clinical trials to investigate namilumab as a potential new treatment for sarcoidosis to significantly improve patients’ overall quality of life.